Tag: Cancer: Pancreatic
Minorities, Women Underrepresented in Pancreatic Cancer Trials
84.7 percent of patients in clinical trials were White and 54.8 percent were men; underrepresentation seen in trials of nearly all phases
Mortality Risk Up for Fragmented Care After Complex Cancer Surgery
Mortality higher for patients readmitted to outside hospital rather than index hospital after hepatopancreatobiliary or gastric cancer surgery
Margin-Positive Surgery Still Beneficial in Pancreatic Cancer
Survival benefit seen for surgery, even with R1/R2 resection margins compared with chemotherapy alone for stage II pancreatic cancer
Perioperative Chemo Feasible for Resectable Pancreatic Cancer
Phase 2 randomized trial revealed similar overall survival for two active regimens compared with adjuvant therapy
Opioid Use May Contribute to Risk for Pancreatic Cancer
At the state level, opioid death rate at four years prior predicted the initial incidence of pancreatic cancer
UEG: Pancreatic CA Down With Bariatric Sx for Obese With DM
Prevalence of pancreatic cancer higher in patients with predisposing diabetes and obesity without BS
Recent Diabetes + Weight Loss Tied to Pancreatic Cancer Risk
Risk higher for those with recent-onset T2DM and weight loss of 1 to 8 pounds, more than 8 pounds
Platinum Therapy May Up Survival in Pancreatic Cancer With DNA Repair Defects
PFS longer in pancreatic ductal adenocarcinoma with versus without homologous recombination deficiency
Clinical, Genetic, Biomarker Model IDs Risk for Pancreatic Cancer
Area under the ROC curve estimated by cross-validation was 0.62 for multifactor model
Molecularly Matched Therapy Promising in Pancreatic Cancer
Overall survival significantly longer for patients with actionable molecular alterations receiving matched tx
